Kuehn Law is investigating Regenxbio, Inc. for allegedly providing false or misleading information about the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on ongoing Phase I/II study data. Shareholders who bought Regenxbio stock before February 9, 2022, are encouraged to contact the law firm to potentially enforce their rights. This case highlights concerns about transparency and accuracy in biotech trial reporting, which can impact investor decisions and market trust.
A landmark P4 randomized trial showed that CT-guided percutaneous coronary intervention (PCI) delivers clinical outcomes comparable to the gold-standard intravascular ultrasound (IVUS) at one year, while reducing procedure time by 27% and contrast us...
Solana Mobile experienced a security breach where an attacker accessed its publishing portal and altered parts of its dApp Store, introducing a malicious app called "SKR Claim" that requested users' seed phrases. The app was visible in the App Spotli...
Bitcoin is recovering to around $78,000 after a sharp October selloff that pushed it below $77,000, but it faces challenges from significant institutional outflows, with U.S. spot Bitcoin ETFs losing $643 million in one session. The cryptocurrency mu...
Hyperliquid's native token HYPE is trading at $88, about 10% below its $98 record high, driven by ICE's plan to launch Hyperliquid perpetual futures in the U.S., pending CFTC approval. The token's market cap would need to grow by $2.3 billion to reac...
Analysts identified four Tron blockchain routes used to move $140 million from the Binance hack, focusing on funds not yet frozen on Tron. The FBI's October 31 request aims to block related funds and includes THORChain node operators and downstream f...
